- Registration for HDSA’s 39th Annual Convention is now open!
- HDSA Human Biology Fellow publishes work on brain connectivity in HD
- New HD Research on the Horizon in 2024
Registration for HDSA’s 39th Annual Convention is now open!
Join HDSA in Spokane, Washington, from May 30-June 1, 2024 for the 39th Annual Convention! To reserve your spot today or learn more about Convention scholarships, click here. Convention will feature lots of research programming, including a showcase of currently recruiting clinical trials, an opportunity to ask HD scientists questions, talks from HDSA-funded researchers, and more. We hope to see you there!
HDSA Human Biology Fellow publishes work on brain connectivity in HD
Researchers from Barcelona, including 2019 HDSA Human Biology Project Fellow Dr. Saül Martinez-Horta, recently published a study of how early symptoms of HD may correspond with changes in brain activity. The study observed changes in movement, thinking, and day-to-day function in people with HD, and compared this with changes in the structure and function of their brains over two years. The study found that brain activity may change to compensate for the onset of HD symptoms. You can read more about the study here.
New HD Research on the Horizon in 2024
A new year has brought exciting new developments in HD research. Rumi Scientific and X-Chem have entered into a new partnership to develop a novel treatment for HD, Voyager Therapeutics and Novartis are teaming up to develop a gene therapy for HD, and a UK-based biotech company, Harness Therapeutics, is making moves to prioritize HD in their research pipeline. These headlines are early indicators of new drugs in development, and it’s exciting to see both familiar names returning to HD research and new players entering the scene.